The FDA's approval of panobinostat (Farydak) for multiple myeloma, the first histone deacetylase (HDAC) inhibitor to be approved in this space, provides a new option and new hope for patients with this disease, Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation, said.
Results of a new study may help boost lung cancer clinical trial enrollment.
With a career as remarkable and distinguished as Joan Lunden's, it's really no surprise that she took on her latest challenge-a diagnosis of triple-negative breast cancer-with such determination and grace.
The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who discussed his position at the 32nd Annual Miami Breast Cancer Conference on Sunday.
Eight signs now identified.
Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.
Pain in patients with breast cancer who have had surgery or who have late-stage disease is common, and managing it effectively can be difficult.
Two new studies highlight the need for cancer survivors and their families to get guidance on healthy lifestyle changes and when the best time might be to integrate them.
The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.
Online patient education program provides short videos.
SPOHNC is very pleased to announce that the long-anticipated and updated version of We Have Walked in Your Shoes: A Guide to Living with Oral, Head, and Neck Cancer Second Edition is now available!
Women with HR-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent- tamoxifen compared with standard tamoxifen alone, according to results from the phase III SOFT trial.
The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.
A study involving more than 1000 patients enrolled in randomized clinical trials has found that patient and physician assessment of treatment toxicities can vary greatly, and they are frequently under-reported by physicians.
A study has found that a large number of women diagnosed with breast cancer know little about the basic characteristics of the cancer:
The Center for Medicare & Medicaid Services (CMS) has announced a new initiative which it hopes will improve the coordination and quality of cancer care for Medicare patients with cancer while also reducing costs.
A new analysis has shown that taking hormone replacement therapy to alleviate symptoms associated with menopause significantly increases the risk of developing the two most common types of ovarian cancer, even if the therapy is only taken for a few years.
Camille Grammer, Real Housewife of Beverly Hills and one-year survivor of endometrial cancer, will lend her voice and celebrity to raising awareness about gynecologic cancers by serving as Chair of the 2015 National Race to End Women's Cancer to be held Sunday, Nov. 8 in Washington, D.C.
Older adults are at higher risk for interactions
Founded in 2005 and located in Alexandria, Virginia, Fight Colorectal Cancer demands a cure for colon and rectal cancer.
Although some physicians may blame patient demands for the increase in medical costs, a new study has shown that cancer patients rarely push their doctor to run unnecessary tests and treatments.
In February 2002, I was diagnosed with stage I melanoma.
When survivors of colorectal cancer smoke, their risk of death more than doubles compared with their counterparts who do not smoke, a new study by researchers at the American Cancer Society has found.
The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.
This section provides you with brief background information about kidney cancer and some immediate resources that may be helpful.
Part II of a series on these new agents
When a cancer diagnosis occurs during this time, physicians and nurses must take special care to discuss certain issues that they may not discuss with pediatric or adult patients.
The big difference in progression-free survival seen in pivotal trial data propelled palbociclib to its accelerated FDA approval for the treatment of metastatic breast cancer, bringing with it the potential for the drug to quickly become adapted as the new standard of care, Brian Wojciechowski, MD, said.
Thanks to The Cancer Genome Atlas (TCGA) Research Network, researchers now have a better understanding of genomic alternations in head and neck cancers.
The recent extended approval of ibrutinib for the treatment of Waldenström's macroglobulinemia (WM), the disease's first FDA-approved therapy, has provided new hope for patients with the orphan disease.
